Table 3.
Summary of Clinical Applications of Colistin Sulfate Reported in the Literature
| Medication | Dosage Regimen | Treatment Duration (Days) | Bacteria | Number of Cases | Clinical Response | Nephrotoxicity | References |
|---|---|---|---|---|---|---|---|
| IV+As/IV+ITH | IV 1.5 million U2–3times/dy; As0.25 million Uq12h IVT/ITH 50000 U q24h |
11.63±5.96 | CRO | 42 | 59.52% | None | [4] |
| IV+As | As 0.5–1.0 million U/day | 8.8±1 | MDR-GNB | 9 | 88.90% | None | [6] |
| IV | IV 10,000–20,000 U/kg | - | CRO | 80 | 73.1–94.4% | 6.30% | [7] |
| IV | IV 1.0 million U BID | 14 | MDR-AB | 39 | 87.20% | 5.10% | [8] |
| IV | IV 0.5–1.5 million U/day | 22.2 (10—55) | MDR-GNB | 10 | 75.00% | None | [9] |
| IV | IV 1.0–1.5 million U/day | 14.35 (14~21) | PDR-AB PDR-PA | 15 | 90.00% | 6.70% | [10] |
| IV | IV 1.0–1.5 million U/day | 22.3±6.2 | MDR-GNB | 15 | 73.30% | None | [11] |
| IV | IV 1.5 million U/day | - | CRAB CRKP | 20 | 75.00% | None | [12] |
| IV | IV 1.0–1.5 million U/day | - | CRO | 50 | 58.00% | 6.00% | [13] |
| IV+As /Iv | As 0.25 million U q12h | 14 | MDR-GNB | 116 | 71.00%/41.9% | 16.10%/9.7% | [14] |
| IV | 2.0 million U/day | 35 (23–59) | CRO | 119 | 53.80% | 9.20% | [15] |
| IV+IVT | IV 0.5 million U q8h IVT 50000 U qd | 9 | MDR-AB | 1 | 100.00% | None | [16] |
| IV+ITH | IV 0.75 million U q12h ITH 50000 U qd/qod |
- | CRKP | 1 | 100.00% | None | [17] |
| IV+As | IV 0.75 million U q12h As 0.25 million U q12h |
6 | XDRAB | 1 | 100.00% | None | [18] |
Abbreviations: IV, intravenous; As, aerosolise; ITH, intrathecal; IVT, intraventricular; MDR-GNB, multidrug-resistant gram-negative bacteria; AB, Acinetobacter baumannii; CR, carbapenem-resistant; KP, Klebsiella pneumoniae; PA, Pseudomonas aeruginosa; PDR, pan-drug resistance.